In early September, the European Medicines Agency (EMA) approved the updated BA.1 vaccines from Pfizer-BioNTech and Moderna
The European Medicines Agency (EMA) has approved this Monday an anticovid vaccine developed by Pfizer/BioNTech to combat subvariants of omicron BA.4/5, which escape the immune system more easily than previous strains.
Although existing coronavirus vaccines provide good protection against hospitalization and death, their effectiveness has declined as the virus has evolved. So, at the beginning of this September, the EMA approved updated BA.1 vaccines from Pfizer-BioNTech and Moderna.
EU officials have signaled in recent months that are open to initially using vaccines targeting the BA.1 variant plus since those specifically directed at the new offspring of Omicron BA.4/5 are more delayed in their development.
Dose of Moderna in the UK
The Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA, for its acronym in English) approved in mid-August the first covid bivalent vaccine–19, effective both against the original variant of SARS-CoV-2 and against omicron.
It was an update of the vaccine manufactured by the American company Moderna, and was approved for booster dose in adults “After verifying that it meets the safety, quality and efficacy standards,” according to the British regulatory body.
Monkeypox vaccination
Related news
This same Monday, the Department of Health has enabled a new vaccination point against monkeypox disease in Barcelona Fairwhich is added to the 18 hospital centers and reference points for sexually transmitted diseases throughout Catalonia, the ‘conselleria’ has informed through an informative note.
Thus, you can now make an appointment through the portal www.vaccinaverola.gencat.cat and make an appointment for Tuesday the 13th from nine in the morning. To facilitate access to vaccination, this point will be available on seven days a week, morning and afternoonand all people living in Catalonia can be vaccinated, Salut has reported.